Company release
23.00 Finnish time / 22.00 Swedish time
Person subject to the notification requirement
Position: Chief Executive Officer
Issuer:
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 48940/6/6
Transaction date: 2024-01-10
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Made under life insurance policy
Transaction details
(1): Volume: 204000 Unit price:
Aggregated transactions (1):
Volume: 204000 Volume weighted average price:
For further information, please contact:
Albert Haeggström, CFO
albert.haeggstrom@nanoform.com
+358 29 370 0150
For investor relations queries, please contact:
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/nanoform-finland-plc---manager-s-transactions---edward-haeggstrom,c3907235
https://mb.cision.com/Main/18905/3907235/2533499.pdf
(c) 2024 Cision. All rights reserved., source